

Nemaura Medical Inc

09:20 01 Apr 2020

Nemaura repurposes SugarBEAT glucose monitor to track the fever caused by coronavirus

Nemaura Medical Inc (NASDAQ:NMRD), the company behind the SugarBEAT non-invasive continuous glucose monitor, announced a plan on Wednesday to repurpose its device as a continuous temperature monitor (CTM) to track the fever caused by the coronavirus (COVID-19).

SugarBEAT includes a patch worn on the skin to monitor glucose levels, but it also contains a built-in thermistor capable of continuously tracking body temperature through the skin. From there, that data can be transmitted via Bluetooth to a cell phone.

The company is currently exploring ways to expedite the launch of a CTM, including possible partnerships and direct-to-consumer sales. The SugarBEAT device has already received its CE mark from regulators in Europe and is currently in production in the UK.

READ: Nemaura to launch digital healthcare subscription service proBEAT in US

"We see a significant commercial opportunity to utilise our BEAT platform technology specifically for CTM purposes with data being automatically sent by low energy Bluetooth to a mobile phone app from which it can then be reviewed by the user and/or sent to a family member or caregiver," Nemaura CEO Faz Chowdhury said in a statement.

"We believe that there are parallels between family members and caregivers remotely monitoring glucose fluctuations in a person, and monitoring fever caused by viral infections, providing a means of remote tracking and intervention. In the current climate we see this as an opportunity to contribute to general wellbeing and patient management," he added.

The coronavirus, in addition to several other diseases, is characterized by a fever, which makes temperature monitoring crucial in detecting the virus and stopping potential spread through early self-isolation. Tracking temperature over time could help physicians analyze the effectiveness of treatments and achieve better outcomes, the company said.

"Body temperature can vary depending on the age of the person, their level of (recent) physical activity, the time the measurement is taken and, importantly, where on the body the temperature is taken," Chowdhury said.

"For this reason, I believe that the ability to track the temperature continuously over time and measure the rate at which it is rising or falling would be a superior form of monitoring a person than sporadic measurements taken using a more traditional thermometer."

Aside from the coronavirus, the company noted several other potential uses for a CTM, including tracking ovulation to improve the chance of conception and predicting diabetes-related foot complications, which can cause ulcers or even

Price: 8.8

Market Cap: \$183.11 m

1 Year Share Price Graph



July 2019 December 2019 June 2020

Share Information

Code: NMRD

Listing: NASDAQ

52 week High Low
16.35 2.5

Sector: Medical technology & services

Website: www.nemauramedical.com

Company Synopsis:

Nemaura Medical Inc. is a medical technology company which has developed sugarBEAT® as a non-invasive, affordable and flexible continuous glucose monitor (CGM) designed to improve glucose management for all people with diabetes and pre-diabetics.

action@proactiveinvestors.com

lead to amputation.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter [@andrew_kessel](https://twitter.com/andrew_kessel)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Nemauro Medical Inc named herein, including the promotion by the Company of Nemauro Medical Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).